OSE Immunotherapeutics has announced that it will present new data on a novel first-in-class FPR2 agonist monoclonal antibody at the upcoming American Association of Immunologists (AAI) 2026 Annual Meeting.

The antibody is designed to activate the formyl peptide receptor 2 (FPR2), a key regulator involved in resolving inflammation. Unlike conventional anti-inflammatory therapies that suppress immune responses, this approach aims to actively promote the natural resolution of chronic inflammation, representing a differentiated therapeutic strategy.

The company’s candidate leverages a novel mechanism of action to “switch off” persistent inflammatory processes while preserving immune system function. This is particularly relevant for chronic inflammatory and immune-mediated diseases, where current treatments often rely on long-term immunosuppression and may be associated with safety concerns.

OSE Immunotherapeutics’ broader pipeline focuses on developing first-in-class immunotherapies across immuno-oncology and immuno-inflammation. The FPR2 agonist program is part of its efforts to address unmet medical needs by targeting underlying disease pathways rather than only managing symptoms.

The data presentation at AAI 2026 is expected to provide insights into the preclinical and translational potential of this antibody, including its ability to modulate inflammatory pathways and restore immune balance. The AAI Annual Meeting serves as a key platform for showcasing advances in immunology research and therapeutic innovation.

Chronic inflammation is increasingly recognized as a central driver of a wide range of diseases, including autoimmune disorders and certain cancers. By focusing on resolution biology, OSE Immunotherapeutics is advancing a new class of therapies that may offer improved efficacy and safety compared to traditional anti-inflammatory treatments.